Skip to main content
SpringerLink
Log in

Wirksamkeit der JAK 1/2-Inhibition von molekularem Risiko unabhängig

Myelofibrose (MF)

  • infopharm
  • Published:
Info Onkologie Aims and scope

Von einer JAK 1/2-Inhibition profitieren MF-Patienten mit hohem sowie niedrigem molekularem Risiko.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Satellitensymposium „Optimizing Therapeutic Approaches in MF and PV“ anlässlich des EHA-Kongresses 2014, Mailand, Italien, 12. Juni 2014; Veranstalter: Novartis Pharma

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Günter Springer

Authors
  1. Günter Springer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Springer, G. Wirksamkeit der JAK 1/2-Inhibition von molekularem Risiko unabhängig. Info Onkol. 17, 53 (2014). https://doi.org/10.1007/s15004-014-0908-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-014-0908-9

Search

Navigation